These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 22362605)

  • 21. Current and future chemical therapies for treating anaemia in chronic kidney disease.
    Locatelli F; Del Vecchio L; Luise MC
    Expert Opin Pharmacother; 2017 Jun; 18(8):781-788. PubMed ID: 28443351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging drugs--potential for misuse in sport and doping control detection strategies.
    Thevis M; Schänzer W
    Mini Rev Med Chem; 2007 May; 7(5):531-7. PubMed ID: 17504189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigational therapies for renal disease-induced anemia.
    Schmid H; Jelkmann W
    Expert Opin Investig Drugs; 2016 Aug; 25(8):901-16. PubMed ID: 27122198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of cobalt for human sports drug testing purposes using ICP- and LC-ICP-MS.
    Knoop A; Planitz P; Wüst B; Thevis M
    Drug Test Anal; 2020 Nov; 12(11-12):1666-1672. PubMed ID: 33142033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials.
    Higashijima Y; Tanaka T; Nangaku M
    Expert Opin Drug Discov; 2013 Aug; 8(8):965-76. PubMed ID: 23642028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Doping control analysis of trimetazidine and characterization of major metabolites using mass spectrometric approaches.
    Sigmund G; Koch A; Orlovius AK; Guddat S; Thomas A; Schänzer W; Thevis M
    Drug Test Anal; 2014; 6(11-12):1197-205. PubMed ID: 24913825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging drugs: mechanism of action, mass spectrometry and doping control analysis.
    Thevis M; Thomas A; Kohler M; Beuck S; Schänzer W
    J Mass Spectrom; 2009 Apr; 44(4):442-60. PubMed ID: 19373874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detecting doping use: more than an analytical problem.
    Delanghe JR; Maenhout TM; Speeckaert MM; De Buyzere ML
    Acta Clin Belg; 2014; 69(1):25-9. PubMed ID: 24635395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging drugs for the treatment of kidney disease-induced anemia.
    Malyszko J; Malyszko JS
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):315-30. PubMed ID: 27537859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implementation of the HIF activator IOX-2 in routine doping controls - Pilot study data.
    Görgens C; Guddat S; Bosse C; Knoop A; Geyer H; Thevis M
    Drug Test Anal; 2020 Nov; 12(11-12):1614-1619. PubMed ID: 32809277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urine analysis concerning xenon for doping control purposes.
    Thevis M; Piper T; Geyer H; Schaefer MS; Schneemann J; Kienbaum P; Schänzer W
    Rapid Commun Mass Spectrom; 2015 Jan; 29(1):61-6. PubMed ID: 25462364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methods for detection and confirmation of Hematide™/peginesatide in anti-doping samples.
    Leuenberger N; Saugy J; Mortensen RB; Schatz PJ; Giraud S; Saugy M
    Forensic Sci Int; 2011 Dec; 213(1-3):15-9. PubMed ID: 21816551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sports drug testing for erythropoiesis-stimulating agents and autologous blood transfusion.
    Reichel C
    Drug Test Anal; 2012 Nov; 4(11):803-4. PubMed ID: 22927317
    [No Abstract]   [Full Text] [Related]  

  • 34. Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat.
    Bao W; Qin P; Needle S; Erickson-Miller CL; Duffy KJ; Ariazi JL; Zhao S; Olzinski AR; Behm DJ; Pipes GC; Jucker BM; Hu E; Lepore JJ; Willette RN
    J Cardiovasc Pharmacol; 2010 Aug; 56(2):147-55. PubMed ID: 20714241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mass spectrometric determination of gonadotrophin-releasing hormone (GnRH) in human urine for doping control purposes by means of LC-ESI-MS/MS.
    Thomas A; Geyer H; Kamber M; Schänzer W; Thevis M
    J Mass Spectrom; 2008 Jul; 43(7):908-15. PubMed ID: 18563864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mass spectrometric detection of peginesatide in human urine in doping control analysis.
    Möller I; Thomas A; Delahaut P; Geyer H; Schänzer W; Thevis M
    J Pharm Biomed Anal; 2012 Nov; 70():512-7. PubMed ID: 22884786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls.
    Thevis M; Schänzer W
    J Pharm Biomed Anal; 2014 Dec; 101():66-83. PubMed ID: 24906629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Annual banned-substance review: analytical approaches in human sports drug testing.
    Thevis M; Kuuranne T; Geyer H; Schänzer W
    Drug Test Anal; 2015 Jan; 7(1):1-20. PubMed ID: 25545248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New Treatment Approaches for the Anemia of CKD.
    Bonomini M; Del Vecchio L; Sirolli V; Locatelli F
    Am J Kidney Dis; 2016 Jan; 67(1):133-42. PubMed ID: 26372086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analytical challenges in the detection of peptide hormones for anti-doping purposes.
    Barroso O; Handelsman DJ; Strasburger C; Thevis M
    Bioanalysis; 2012 Jul; 4(13):1577-90. PubMed ID: 22831474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.